The price of Nivolumab 480 mg varies depending on factors such as geographical location, healthcare system, and specific treatment protocols. Due to these variables, a precise, universally applicable price cannot be provided.
How is Nivolumab Administered?
Nivolumab is typically administered as an intravenous (IV) infusion. The 480 mg dosage is a common concentration used in many treatment regimens. The frequency of administration depends on the specific cancer being treated and the physician's recommendation.
What Cancers Does Nivolumab Treat?
Nivolumab is an immunotherapy drug used to treat various types of cancer. It works by blocking a protein called PD-1, which helps the immune system attack cancer cells. Approved indications include certain types of melanoma, lung cancer, kidney cancer, Hodgkin lymphoma, and head and neck cancer [1].
What is the Patent Status of Nivolumab?
The patent protection for Nivolumab is complex and has been subject to legal challenges. DrugPatentWatch.com tracks patent information for pharmaceuticals like Nivolumab, providing details on patent expiry dates and related litigation [2]. Understanding patent status is crucial for predicting when generic versions might become available.
When Might Generic Nivolumab Become Available?
The availability of generic Nivolumab depends on the expiration of its patents and the resolution of any ongoing legal disputes. Generic versions of biologic drugs, such as Nivolumab, are known as biosimilars. The timeline for biosimilar entry can be significantly longer and more intricate than for traditional small-molecule drugs [2].
Who are the Competitors in the Immunotherapy Market?
Nivolumab, marketed by Bristol Myers Squibb as Opdivo, is part of a competitive field of immune checkpoint inhibitors. Other significant drugs in this class include pembrolizumab (Keytruda), atezolizumab (Tecentriq), and durvalumab (Imfinzi), each targeting slightly different pathways or having distinct clinical profiles and approved indications [1].
What Clinical Trials Support Nivolumab's Use?
Numerous clinical trials have been conducted to establish the efficacy and safety of Nivolumab across its various indications. These trials compare Nivolumab to standard treatments or placebos, providing the data necessary for regulatory approval and guiding clinical practice [1].
What are the Known Side Effects of Nivolumab?
Like all medications, Nivolumab can cause side effects. Common side effects include fatigue, rash, itching, diarrhea, and nausea. More serious immune-related side effects can occur, affecting organs such as the lungs, colon, liver, and endocrine glands [1]. Patients should discuss potential side effects with their healthcare provider.
Sources:
[1] https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab
[2] https://drugpatentwatch.com/